Theravance Biopharma (NASDAQ:TBPH) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Theravance Biopharma (NASDAQ:TBPH – Free Report) from a buy rating to a strong-buy rating in a research report sent to investors on Sunday morning.

TBPH has been the subject of several other research reports. HC Wainwright lifted their price objective on Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Wednesday, October 8th. BTIG Research upped their price target on shares of Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, November 26th. Zacks Research downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Finally, Oppenheimer began coverage on shares of Theravance Biopharma in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $27.80.

Get Our Latest Analysis on TBPH

Theravance Biopharma Stock Down 1.4%

Shares of TBPH stock opened at $17.53 on Friday. The company has a 50 day moving average price of $16.47 and a 200-day moving average price of $13.78. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $20.33. The firm has a market capitalization of $888.25 million, a PE ratio of 30.75 and a beta of 0.14.

Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last issued its earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.10. The company had revenue of $19.99 million for the quarter, compared to analysts’ expectations of $19.89 million. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. Analysts anticipate that Theravance Biopharma will post -1.09 earnings per share for the current year.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total value of $582,506.25. Following the completion of the sale, the senior vice president directly owned 277,695 shares of the company’s stock, valued at approximately $5,206,781.25. This represents a 10.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of institutional investors have recently bought and sold shares of TBPH. Quarry LP bought a new position in shares of Theravance Biopharma during the 3rd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd lifted its position in Theravance Biopharma by 107.4% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares in the last quarter. CIBC Private Wealth Group LLC increased its holdings in shares of Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 4,662 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Theravance Biopharma during the 3rd quarter valued at about $101,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

(Get Free Report)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Recommended Stories